CSIMarket Company Name, Ticker, Customers, else..
 
Synaptogenix Inc   (SNPX)
Other Ticker:  
 
 
Price: $3.0700 $-0.09 -2.848%
Day's High: $3.18 Week Perf: -13.28 %
Day's Low: $ 3.01 30 Day Perf: -17.47 %
Volume (M): 17 52 Wk High: $ 11.48
Volume (M$): $ 52 52 Wk Avg: $5.39
Open: $3.18 52 Wk Low: $2.72



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Synaptogenix Inc
Synaptogenix Inc is a biotechnology company focused on developing therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. The company specializes in targeting the build-up of amyloid plaques in the brain, a characteristic feature of Alzheimer's disease. Synaptogenix's leading drug candidate is Bryostatin-1, which has shown potential in preclinical and clinical studies for the treatment of Alzheimer's disease. The company aims to advance Bryostatin-1 through clinical trials and ultimately provide an effective treatment option for patients suffering from neurodegenerative diseases.


   Company Address: 1185 Avenue of the Americas New York 10036 NY
   Company Phone Number: 242-0005   Stock Exchange / Ticker: NASDAQ SNPX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Synaptogenix Inc

Synaptogenix Inc Shows Improvement in Operating Shortfall in First Quarter of 2024

Over the past five trading days, Synaptogenix Inc shares have experienced a decline of -2.97%. This downward trend has contributed to a year-to-date performance of -37.97%. Additionally, Synaptogenix Inc shares are currently trading at a level that is only 29.6% higher than their 52-week low.
During this time, the Major Pharmaceutical Preparations industry insiders have been analyzing the results of the first quarter of 2024. Of particular note is the operating shortfall of $-1.691494 million that Synaptogenix Inc reported for the period from January to March 31, 2024. It is important to highlight that the company did not disclose any revenue for this quarter.
Comparing these results to the first quarter of 2023, where the operating shortfall was $-2.921941 million, it is evident that Synaptogenix Inc has experienced an improvement. This improvement can be seen as a positive sign for the overall condition of the company.
Synaptogenix Inc

Synaptogenix Inc Shows Resilience Despite Operating Deficit in Fourth Quarter of 2023



Synaptogenix Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal period of October to December 31, 2023. Despite reporting a net deficit and overall decline in revenue, the company's operating deficit and improved performance compared to the previous year have provided some optimism among analysts. Additionally, the company's stock performance has experienced a decline over the past 30 days and year to date. This article aims to analyze these financial results, provide context, and evaluate the implications for Synaptogenix Inc.
Financial Results:
1. Operating Deficit: Synaptogenix Inc recorded an operating deficit of $-2.132408 million in the fiscal period of October to December 31, 2023. This is a significant improvement from the comparable period the previous year, which reported a deficit of $-5.888867 million.
Synaptogenix Inc

Synaptogenix Inc's Remarkable Turnaround: Major Pharmaceutical Preparations Industry Sees Boost in Q3 2023 Earnings


As a financial analyst for The , it is my duty to interpret the financial results of companies across various industries. Today, we delve into the Major Pharmaceutical Preparations industry, focusing on the performance of Synaptogenix Inc (SNPX).
SNPX has recently released its results for the third quarter of 2023, revealing an operating deficit of $-1.429792 million. While this might appear disheartening on the surface, it is important to recognize the improvement from the corresponding period the previous year, where the deficit stood at $-3.167206 million. This considerable reduction demonstrates that SNPX is moving in a positive direction and has gained favor among market participants.
Synaptogenix Inc

Synaptogenix Inc's Latest Financial Results Reveal Promising Signs of Growth Amidst Operating Loss of $-1.8 Million



In the Major Pharmaceutical Preparations industry, while the big players dominate the headlines, there are some lesser-known businesses making significant strides. Synaptogenix Inc (SNPX) recently announced its financial results for the second quarter of 2023, revealing an operating loss but also showcasing promising signs of growth. This report delves into the details of Synaptogenix Inc's performance, highlighting key takeaways and discussing the company's future prospects.
Operating Loss:
Synaptogenix Inc disclosed an operating loss of $-1.829713 million for the second quarter of 2023. Despite this loss, it is crucial to note that the company is currently in an expansion phase, which signifies its efforts to invest in strategic initiatives and develop its portfolio. The operating loss in the present quarter surpassed the figure reported for the same period last year, indicating Synaptogenix Inc's dedication towards growth.
Synaptogenix Inc

Synaptogenix Inc Extends Loss Streak with Operating Loss in Q1 2023 - Urgent Questions Over Company's Future Viability

The pharmaceutical industry has been facing significant challenges in recent times, and the latest earnings report by Synaptogenix Inc (SNPX) only serves to reinforce the bearish outlook that investors have been dreading. For the earnings cycle of fiscal January to March 31 2023, the company reported an operating loss of $-2.921941 million, which is indeed a cause for concern. While it is commendable that the company managed to operate more cost-effectively than it did in the same time-frame a year ago, it is clear that its financial performance is still far from impressive.
One of the primary aspects that investors must consider when evaluating Synaptogenix's fiscal first quarter of 2023 is its net income, which declined by a whopping -31.54% to $2.244 million. This decline is a clear indication that the company is struggling to generate revenue, and it raises questions about its long-term viability in an industry that is becoming increasingly competitive.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com